Publication | Closed Access

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model

Neuro-oncologyNanomedicineLipid-based Nanoparticulate FormulationNanotherapeuticsDrug TargetingGliomaTherapeutic NanomaterialsMedicinePharmaceutical NanotechnologyDrug Delivery SystemsNano-drug DeliveryTumor TargetingIrinophore C™PharmacologyRadiation OncologyOrthotopic Glioblastoma ModelDrug Discovery